TMCI
Get informed when a big investor buys or sells
+ FollowOvervalued by 129% based on the discounted cash flow analysis.
| Market cap | $301.66 Million |
|---|---|
| Enterprise Value | $302.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.93 |
| Beta | 1.4 |
| Outstanding Shares | 65,049,844 |
| P/E Ratio | -5 |
|---|---|
| PEG | 57.04 |
| Price to Sales | 1.63 |
| Price to Book Ratio | 4.88 |
| Enterprise Value to Revenue | 1.47 |
| Enterprise Value to EBIT | -5.41 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.19 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 105,500▲ Infinity% |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 49.41%▼ 6.30% |
|---|---|
| Total Invested | $127.94M▲ 164.88% |
| Investors Holding | 122▲ 5.00% |
No data
Based in Ponte Vedra, FL, Treace Medical Concepts, Inc. is a privately-held medical device company focused on advancing the standard of care for the surgical management of bunion deformities. The Company’s patented Lapiplasty® 3D Bunion ...